Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.62 |
| ▸ | GNPAT | O15228 | 1/20 | 0.60 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.57 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.57 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.53 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.53 |
| ▸ | CALCRL | Q16602 | 2/20 | 0.52 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.52 |
| ▸ | CHRNG | P07510 | 1/20 | 0.52 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.52 |
| ▸ | CHRND | Q07001 | 1/20 | 0.52 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.52 |
| ▸ | ECE1 | P42892 | 1/20 | 0.52 |
| ▸ | GHSR | Q92847 | 1/20 | 0.51 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1711937 | 1.00 | SLC15A2 (0.62) | SLC15A2GNPATITGB3ITGA2BERAP2 | |
| SCHEMBL30900769 | 0.95 | SLC15A2 (0.58) | SLC15A2GNPATITGB3ITGA2BERAP2 | |
| SCHEMBL29574640 | 0.94 | SLC15A2 (0.57) | SLC15A2GNPATITGB3ITGA2BERAP2 | |
| SCHEMBL31556273 | 0.93 | GNPAT (0.60) | SLC15A2GNPATITGB3ITGA2BERAP2 | |
| SCHEMBL31181203 | 0.92 | GNPAT (0.57) | SLC15A2GNPATITGB3ITGA2BERAP2 | |
| SCHEMBL29904367 | 0.91 | OPRK1 (0.56) | SLC15A2GNPATGHSR | |
| SCHEMBL9318080 | 0.90 | SLC15A2 (0.60) | SLC15A2ERAP2LNPEPCHRNA1CHRNG | |
| SCHEMBL9318061 | 0.90 | SLC15A2 (0.60) | SLC15A2ERAP2LNPEPCHRNA1CHRNG | |
| SCHEMBL7122844 | 0.89 | SLC15A2 (0.59) | SLC15A2ERAP2LNPEPCHRNA1CHRNG | |
| SCHEMBL30744249 | 0.89 | GNPAT (0.57) | SLC15A2GNPATITGB3ITGA2BERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 521 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144882-A1 | ANTI-NECTIN-4 ANTIBODY DRUG CONJUGATE AND USE THEREOF | BIO-THERA SOLUTIONS, LTD. (CN) | 2026-05-28 | — | — | US | claimed |
| US-20260124212-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | IMMUNOGEN INC (US) | 2026-05-07 | — | — | US | claimed |
| US-20260008848-A1 | ANTI-NECTIN-4 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | BIO THERA SOLUTIONS LTD (CN) | 2026-01-08 | — | — | US | claimed |
| US-20260007763-A1 | PEGYLATED ANTIBODY HYDROXYL-BEARING DRUG CONJUGATE | SHENZHEN ENDURING BIOTECH, LTD. (CN) | 2026-01-08 | — | — | US | claimed |
| US-20250381283-A1 | METHOD FOR TREATING SOLID TUMOR | BIO THERA SOLUTIONS LTD (CN) | 2025-12-18 | — | — | US | claimed |
| US-20250333498-A1 | ANTI-CLDN18.2 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | BIO THERA SOLUTIONS LTD (CN) | 2025-10-30 | — | — | US | claimed |
| US-20250262316-A1 | ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF | BIO-THERA SOLUTIONS, LTD. (CN) | 2025-08-21 | — | — | US | claimed |
| US-12390471-B2 | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof | IMMUNOGEN, INC. (US) | 2025-08-19 | — | — | US | claimed |
| US-20250249114-A1 | METHOD FOR TREATING HER2-POSITIVE SOLID TUMOR | BIO-THERA SOLUTIONS, LTD. (CN) | 2025-08-07 | — | — | US | claimed |
| US-20250205348-A1 | NOVEL PEPTIDIC LINKERS AND CRYPTOPHYCIN CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI (FR) | 2025-06-26 | — | — | US | claimed |
| WO-2022175222-A1 | CRYPTOPHYCIN COMPOUNDS AND CONJUGATES THEREOF | UNIVERSITÄT BIELEFELD (DE) | 2022-08-25 | — | — | WO | claimed |
| CN-106604927-B | Cytotoxic benzodiazepine derivatives | 伊缪诺金公司 | 2022-08-09 | — | — | CN | claimed |
| US-20220211648-A1 | COMPOSITIONS, DELIVERY SYSTEMS, AND METHODS USEFUL IN TUMOR THERAPY | INDI MOLECULAR, INC. | 2022-07-07 | — | — | US | claimed |
| US-11332535-B2 | Anti-CD123 antibodies and conjugates and derivatives thereof | IMMUNOGEN, INC. (US) | 2022-05-17 | — | — | US | claimed |
| WO-2022098745-A1 | COMPOSITIONS, DELIVERY SYSTEMS, AND METHODS USEFUL IN TUMOR THERAPY | INDI MOLECULAR, INC. (US) | 2022-05-12 | — | — | WO | claimed |
| CN-112604004-B | Anti-human EGFR antibody drug conjugate and preparation method and application thereof | 中国医学科学院医药生物技术研究所 | 2022-05-10 | — | — | CN | claimed |
| US-20220111067-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | IMMUNOGEN SWITZERLAND GMBH (CH) | 2022-04-14 | — | — | US | claimed |
| CN-114222756-A | Biparatopic FR-alpha antibodies and immunoconjugates | 伊缪诺金公司 | 2022-03-22 | — | — | CN | claimed |
| EP-3962935-A1 | BIPARATOPIC FR-ALPHA ANTIBODIES AND IMMUNOCONJUGATES | Immunogen, Inc. (US) | 2022-03-09 | — | — | EP | claimed |
| EP-3941527-A1 | METHODS OF PREPARING CELL-BINDING AGENT-DRUG CONJUGATES | ImmunoGen, Inc. (US) | 2022-01-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008848-A1 | ANTI-NECTIN-4 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | NECTIN4, VSIG8, IGSF11 | SLC15A2 1678/4885GNPAT 3927/4885ITGB3 278/4885 |
| US-20250249114-A1 | METHOD FOR TREATING HER2-POSITIVE SOLID TUMOR | ERBB2, EGFR, ERBB3 | SLC15A2 1036/4885GNPAT 1396/4885ITGB3 2390/4885 |
| US-12390471-B2 | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof | VIP, AREG, MIF | SLC15A2 309/4885GNPAT 2460/4885ITGB3 3421/4885 |
| US-20260144882-A1 | ANTI-NECTIN-4 ANTIBODY DRUG CONJUGATE AND USE THEREOF | NECTIN4, CD22, NGFR | SLC15A2 795/4885GNPAT 2519/4885ITGB3 99/4885 |
| US-20260007763-A1 | PEGYLATED ANTIBODY HYDROXYL-BEARING DRUG CONJUGATE | PTMS, ACP1, CD2 | SLC15A2 3848/4885GNPAT 1213/4885ITGB3 314/4885 |
| US-20220111067-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | VIP, AREG, MIF | SLC15A2 309/4885GNPAT 2460/4885ITGB3 3421/4885 |
| US-20250333498-A1 | ANTI-CLDN18.2 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | CNTN1, EPCAM, SLC22A8 | SLC15A2 49/4885GNPAT 3083/4885ITGB3 484/4885 |
| US-20220211648-A1 | COMPOSITIONS, DELIVERY SYSTEMS, AND METHODS USEFUL IN TUMOR THERAPY | TP53, BAX, RNASE1 | SLC15A2 2378/4885GNPAT 1188/4885ITGB3 2327/4885 |
| US-20260124212-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | VEGFA, VIP, AREG | SLC15A2 73/4885GNPAT 4828/4885ITGB3 2243/4885 |
| US-20250381283-A1 | METHOD FOR TREATING SOLID TUMOR | TPM4, TPM3, TPST2 | SLC15A2 1792/4885GNPAT 1696/4885ITGB3 1045/4885 |
| US-20250205348-A1 | NOVEL PEPTIDIC LINKERS AND CRYPTOPHYCIN CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | RPN1, CLSPN, FRG1 | SLC15A2 2656/4885GNPAT 1890/4885ITGB3 3789/4885 |
| US-11332535-B2 | Anti-CD123 antibodies and conjugates and derivatives thereof | IL23R, CD22, IL2RA | SLC15A2 2378/4885GNPAT 3857/4885ITGB3 18/4885 |
| US-20250262316-A1 | ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF | FCGR2A, FCGR1A, FCGR3B | SLC15A2 699/4885GNPAT 630/4885ITGB3 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.